Dr Sof Andrikopoulos: what’s in store at ADC 2018

With a focus this year on pros and cons of technology in diabetes, the Australasian Diabetes Congress to be held 22-24 August 2018 in Adelaide will bring together Australia’s multidisciplinary partners in diabetes management, research and education.

Organised by the Australian Diabetes Society (ADS) and the Australian Diabetes Educators Association (ADEA) the ADC will be welcoming diabetes specialists from across Australia and New Zealand and also many diabetes experts from China, as part of a unique exchange program.

Dr Sof Andrikopoulos, CEO and Immediate Past President of the Australian Diabetes Society tells the limbic that the ADC meeting will be covering the impact of technologies such as continuous glucose monitoring  in diabetes management.

“With so many new pumps and CGM systems in diabetes we will be looking at how this is affecting the care of patients,” he says.

“Health professionals are now seeing so much data being generated by these technologies but they are asking how does this help them manage the patient with diabetes?”

The ADC meeting will have several international speakers talking about the cutting edge developments in diabetes care and the challenges in its management, says Dr Andrikopoulos, who is Head of the Islet Biology and Metabolism Research Group at the University of Melbourne;

Prof Stephanie Amiel from King’s College, London, where insulin pumps were pioneered, will be discussing reducing risk of hypoglycaemia in diabetes therapies.

From Harvard, Professor Rohit Kulkarmi will be describing the latest developments in stem cells and pancreatic islet cell regeneration.

And Professor Eva Feldman, one of the top neurologists in the US, will be talking about the latest developments in the understanding of neurological complications of diabetes, particularly diabetic neuropathy.

There will be updates on the latest developments in in drug therapies for diabetes, such as the emerging evidence on cardiovascular effects of SGLT2 inhibitors and GLP1 agonists  in type 2 diabetes.

The ADC meeting will also see the launch of new guidelines and recommendations, says Dr Andrikopoulos, including Australia’s first accreditation standards for high-risk foot services from the National Association of Diabetes Centres Foot Network.

“It is going to be a great meeting, I look forward to seeing you there,” he says.

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic